Understanding HIV prevention preferences among cisgender women and trans individuals

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the preferences and attitudes towards HIV prevention methods, specifically pre-exposure prophylaxis (PrEP), among cisgender women and trans individuals. Participants will complete online questionnaires regarding their demographics, health determinants, and preferences for PrEP modalities. The study will also conduct qualitative interviews with individuals who choose not to start or discontinue PrEP to explore their decision-making processes. Additionally, participants taking PrEP will provide dried blood spot samples to measure medication levels and receive personalized feedback on their adherence to the regimen.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Cisgender women and trans individuals who have an indication for PrEP and have 1) decided to take PrEP, 2) decided not to take PrEP, or 3) decided to discontinue PrEP

Exclusion Criteria:

* Cannot provide informed consent
* Living with HIV

Where it's running

• Columbia University Medical Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Magdalena Sobieszczyk, MD, MPH — Columbia University
• Study coordinator: Deborah Theodore, MD
• Email: dat2132@cumc.columbia.edu
• Phone: 2123052201

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing HIV prevention methods during pregnancy and breastfeeding

  This study is testing whether a long-acting injectable HIV prevention method is safer than a daily pill for pregnant women and their babies in Malawi.

  Recruiting Phase 4 University of North Carolina, Chapel Hill · Lilongwe · NCT06158126

• Pharmacist-guided PEP/PrEP Access Using PEPPI Software

  This trial tests whether the PEPPI software helps pharmacists provide PEP/PrEP and helps patients access these HIV prevention options.

  Recruiting Empowerx INC · Del Mar, California · NCT07683117

• Feasibility of Online HIV Prevention Research for People Who Inject Drugs

  This study tests whether online recruitment and at-home HIV testing can be done reliably by and for people who inject drugs.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT07625917

• Host-led harm reduction for men who have sex with men who engage in chemsex in Bangkok

  This project will try a host-led harm reduction approach to reduce substance-related, sexual, mental health, and legal harms among men who have sex with men who engage in chemsex in Bangkok.

  Recruiting Institute of HIV Research and Innovation Foundation, Thailand · Pathum Wan, Bangkok · NCT07512869

• Transgender-tailored harm reduction and PrEP service for people who engage in chemsex in Bangkok

  This project will try a comprehensive harm-reduction service tailored for transgender and non-binary adults in Bangkok who engage in chemsex or substance use to increase PrEP use, reduce HIV/STIs, and address mental health and socio-legal needs.

  Recruiting Institute of HIV Research and Innovation Foundation, Thailand · Pathum Wan, Bangkok · NCT07512856

• See if PrEP Choice helps young people start and stick with HIV prevention methods

  This trial tests whether the PrEP Choice package helps 13-24 year-olds in the U.S. begin and continue using PrEP or DoxyPEP for HIV prevention.

  Recruiting at 6 sites Westat · San Francisco, California and 5 other locations · NCT07510048

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.